Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BI 754091 + Effi-DEM |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 754091 | BI754091|BI-754091|Ezabenlimab | Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 86 | BI 754091 (Ezabenlimab) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212). | |
Effi-DEM | OSE-172|BI 765063|BI-765063|OSE 172 | Immune Checkpoint Inhibitor 146 | Effi-DEM (OSE-172) is a monoclonal antibody to the SIRPa receptor that blocks the CD47-SIRPa interaction to promote macrophage phagocytosis of tumor cells and may stimulate cytotoxic T-cells (PMID: 29873856). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05249426 | Phase I | BI 754091 + Cetuximab + Effi-DEM BI 754091 + BI 836880 + Effi-DEM BI 754091 + Effi-DEM | A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer | Recruiting | USA | FRA | ESP | 2 |
NCT03990233 | Phase I | Effi-DEM BI 754091 + Effi-DEM | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Recruiting | FRA | BEL | 0 |